AstraZeneca PLC (AZN)vsImmuCell Corporation (ICCC)
AZN
AstraZeneca PLC
$166.08
+1.22%
HEALTHCARE · Cap: $257.57B
ICCC
ImmuCell Corporation
$10.13
+1.81%
HEALTHCARE · Cap: $87.01M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 199949% more annual revenue ($61.37B vs $30.68M). AZN leads profitability with a 17.0% profit margin vs 2.6%. AZN trades at a lower P/E of 24.9x. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
ICCC
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$166.08
$29.73 discount
Margin of Safety
+63.5%
Fair Value
$17.78
Current Price
$10.13
$7.65 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Earnings expanding 259.9% YoY
Reasonable price relative to book value
Strong operational efficiency at 26.9%
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Distress zone — elevated risk
Smaller company, higher risk/reward
2.6% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : ICCC
The strongest argument for ICCC centers on EPS Growth, Price/Book, Operating Margin. Revenue growth of 11.5% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : ICCC
The primary concerns for ICCC are Altman Z-Score, Market Cap, Profit Margin. A P/E of 136.9x leaves little room for execution misses. Thin 2.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while ICCC is a value play — different risk/reward profiles.
ICCC carries more volatility with a beta of 0.55 — expect wider price swings.
ICCC is growing revenue faster at 11.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 47/100), backed by strong 17.0% margins. ICCC offers better value entry with a 63.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
ImmuCell Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?